-
-
Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study
inFerring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in…
-
-
Ferring announces results demonstrating the efficacy and safety of follitropin delta for women undergoing in vitro fertilisation using an agonist protocol
inFerring announces results demonstrating the efficacy and safety of follitropin delta for…
-
Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal
inFerring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal…
-
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
inLaunch of two first-in-class medicines in 2023 marks start of exciting phase…
-
Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
in…
PRESS RELEASE 2024
PRESS RELEASE 2024